CLINICAL CHARACTERISTICS AND NATURAL HISTORY OF RHO-ASSOCIATED RETINITIS PIGMENTOSA: A Long-Term Follow-Up Study

Retina. 2021 Jan 1;41(1):213-223. doi: 10.1097/IAE.0000000000002808.

Abstract

Purpose: To investigate the natural history of RHO-associated retinitis pigmentosa (RP).

Methods: A multicenter, medical chart review of 100 patients with autosomal dominant RHO-associated RP.

Results: Based on visual fields, time-to-event analysis revealed median ages of 52 and 79 years to reach low vision (central visual field <20°) and blindness (central visual field <10°), respectively. For the best-corrected visual acuity (BCVA), the median age to reach mild impairment (20/67 ≤ BCVA < 20/40) was 72 years, whereas this could not be computed for lower acuities. Disease progression was significantly faster in patients with a generalized RP phenotype (n = 75; 75%) than that in patients with a sector RP phenotype (n = 25; 25%), in terms of decline rates of the BCVA (P < 0.001) and V4e retinal seeing areas (P < 0.005). The foveal thickness of the photoreceptor-retinal pigment epithelium (PR + RPE) complex correlated significantly with BCVA (Spearman's ρ = 0.733; P < 0.001).

Conclusion: Based on central visual fields, the optimal window of intervention for RHO-associated RP is before the 5th decade of life. Significant differences in disease progression are present between generalized and sector RP phenotypes. Our findings suggest that the PR + RPE complex is a potential surrogate endpoint for the BCVA in future studies.

Publication types

  • Multicenter Study

MeSH terms

  • Acute-Phase Proteins / genetics*
  • Acute-Phase Proteins / metabolism
  • Aged
  • Electroretinography
  • Female
  • Follow-Up Studies
  • Forecasting*
  • Humans
  • Male
  • Middle Aged
  • Phenotype
  • Retinal Pigment Epithelium / pathology*
  • Retinitis Pigmentosa / blood
  • Retinitis Pigmentosa / diagnosis*
  • Retinitis Pigmentosa / genetics
  • Retrospective Studies
  • Tomography, Optical Coherence / methods
  • Visual Acuity*
  • Visual Fields / physiology*

Substances

  • Acute-Phase Proteins
  • acute-phase protein rho